Menu
Search
|

Menu

Close
X

Arcturus Therapeutics Ltd ARCT.OQ (NASDAQ Stock Exchange Global Market)

10.92 USD
+0.31 (+2.92%)
As of 5:35 PM BST
Previous Close 10.61
Open 10.36
Volume 11,394
3m Avg Volume 21,988
Today’s High 10.95
Today’s Low 10.36
52 Week High 15.49
52 Week Low 4.11
Shares Outstanding (mil) 27.56
Market Capitalization (mil) 28.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY19
15
FY18
16
FY17
13
FY16
20
EPS (USD)
FY19
-0.752
FY18
-2.165
FY17
-3.571
FY16
3.675
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
0.71
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
0.00
14.55
LT Debt to Equity (MRQ)
vs sector
0.00
10.20
Return on Investment (TTM)
vs sector
-41.68
14.48
Return on Equity (TTM)
vs sector
-41.68
15.78

EXECUTIVE LEADERSHIP

Peter Farrell
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Joseph Payne
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Andrew Sassine
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
Kevin Skol
Senior Vice President - Business Development & Alliance Management, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10628 Science Center Dr Ste 200
SAN DIEGO   CA   92121-1128

Phone: +1858.9002660

Arcturus Therapeutics Ltd. is a ribonucleic acid (RNA) medicines company. The Company owns Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers. The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis and vaccines. The Company’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The Company's UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes.

SPONSORED STORIES